SCHEMBL2276451

SCHEMBL2276451

O=C(O)c1ccc(CCc2ccccc2)cc1NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.71
MCL1 Q07820 1/20 0.48
BCL2A1 Q16548 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7686172 0.83 ACLY (0.71) ACLYMCL1KDM4EALDH1A1HPGD
SCHEMBL2275253 0.83 ACLY (1.00) ACLYMCL1
SCHEMBL2275449 0.83 METAP2 (0.64) ACLYMCL1BCL2A1KDM4EALDH1A1
SCHEMBL2270968 0.83 ACLY (0.51) ACLYKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6137932 0.82 ACLY (0.69) ACLYKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2273163 0.80 ACLY (0.67) ACLYMCL1ALDH1A1
SCHEMBL27716715 0.80 ACLY (0.67) ACLYMCL1KDM4EALDH1A1HSD17B10
SCHEMBL2271008 0.78 KMT2A (0.56) ACLYMCL1KDM4EALDH1A1HSD17B10
SCHEMBL5147679 0.78 KMT2A (0.56) ACLYMCL1KDM4EALDH1A1HSD17B10
SCHEMBL4217232 0.77 KDM6B (0.61) ACLYMCL1BCL2A1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885MCL1 1774/4885BCL2A1 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.